Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Revisiting inconsistency in large pharmacogenomic studies.

F1000Research

Safikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q, Goldenberg A, Birkbak NJ, Hatzis C, Shi L, Beck AH, Aerts HJWL, Quackenbush J, Haibe-Kains B.
PMID: 28928933
F1000Res. 2016 Sep 16;5:2333. doi: 10.12688/f1000research.9611.3. eCollection 2016.

In 2013, we published a comparative analysis of mutation and gene expression profiles and drug sensitivity measurements for 15 drugs characterized in the 471 cancer cell lines screened in the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer...

Cite
Safikhani Z, Smirnov P, Freeman M, et al. Revisiting inconsistency in large pharmacogenomic studies. F1000Res. 2016;5:2333doi: 10.12688/f1000research.9611.3.
Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J., & Haibe-Kains, B. (2016). Revisiting inconsistency in large pharmacogenomic studies. F1000Research, 52333. https://doi.org/10.12688/f1000research.9611.3
Safikhani, Zhaleh, et al. "Revisiting inconsistency in large pharmacogenomic studies." F1000Research vol. 5 (2016): 2333. doi: https://doi.org/10.12688/f1000research.9611.3
Safikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q, Goldenberg A, Birkbak NJ, Hatzis C, Shi L, Beck AH, Aerts HJWL, Quackenbush J, Haibe-Kains B. Revisiting inconsistency in large pharmacogenomic studies. F1000Res. 2016 Sep 16;5:2333. doi: 10.12688/f1000research.9611.3. eCollection 2016. PMID: 28928933; PMCID: PMC5580432.
Copy Download .nbib Format: NLM
Assessment of pharmacogenomic agreement.

F1000Research

Safikhani Z, El-Hachem N, Quevedo R, Smirnov P, Goldenberg A, Juul Birkbak N, Mason C, Hatzis C, Shi L, Aerts HJ, Quackenbush J, Haibe-Kains B.
PMID: 27408686
F1000Res. 2016 May 09;5:825. doi: 10.12688/f1000research.8705.1. eCollection 2016.

In 2013 we published an analysis demonstrating that drug response data and gene-drug associations reported in two independent large-scale pharmacogenomic screens, Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE), were inconsistent. The GDSC and...

Cite
Safikhani Z, El-Hachem N, Quevedo R, et al. Assessment of pharmacogenomic agreement. F1000Res. 2016;5:825doi: 10.12688/f1000research.8705.1.
Safikhani, Z., El-Hachem, N., Quevedo, R., Smirnov, P., Goldenberg, A., Juul Birkbak, N., Mason, C., Hatzis, C., Shi, L., Aerts, H. J., Quackenbush, J., & Haibe-Kains, B. (2016). Assessment of pharmacogenomic agreement. F1000Research, 5825. https://doi.org/10.12688/f1000research.8705.1
Safikhani, Zhaleh, et al. "Assessment of pharmacogenomic agreement." F1000Research vol. 5 (2016): 825. doi: https://doi.org/10.12688/f1000research.8705.1
Safikhani Z, El-Hachem N, Quevedo R, Smirnov P, Goldenberg A, Juul Birkbak N, Mason C, Hatzis C, Shi L, Aerts HJ, Quackenbush J, Haibe-Kains B. Assessment of pharmacogenomic agreement. F1000Res. 2016 May 09;5:825. doi: 10.12688/f1000research.8705.1. eCollection 2016. PMID: 27408686; PMCID: PMC4926729.
Copy Download .nbib Format: NLM
Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals.

HGG advances

Chen H, Majumdar A, Wang L, Kar S, Brown KM, Feng H, Turman C, Dennis J, Easton D, Michailidou K, Simard J, Bishop T, Cheng IC, Huyghe JR, Schmit SL, O'Mara TA, Spurdle AB, Gharahkhani P, Schumacher J, Jankowski J, Gocke I, Bondy ML, Houlston RS, Jenkins RB, Melin B, Lesseur C, Ness AR, Diergaarde B, Olshan AF, Amos CI, Christiani DC, Landi MT, McKay JD, Brossard M, Iles MM, Law MH, MacGregor S, Beesley J, Jones MR, Tyrer J, Winham SJ, Klein AP, Petersen G, Li D, Wolpin BM, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Brennan P, Chanock SJ, Gaborieau V, Purdue MP, Pharoah P, Hung RJ, Amundadottir LT, Kraft P, Pasaniuc B, Lindström S.
PMID: 34355204
HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100041. Epub 2021 Jun 12.

Genome-wide association studies (GWASs) have identified thousands of cancer risk loci revealing many risk regions shared across multiple cancers. Characterizing the cross-cancer shared genetic basis can increase our understanding of global mechanisms of cancer development. In this study, we...

Cite
Chen H, Majumdar A, Wang L, et al. Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. HGG Adv. 2021;2(3)doi: 10.1016/j.xhgg.2021.100041.
Chen, H., Majumdar, A., Wang, L., Kar, S., Brown, K. M., Feng, H., Turman, C., Dennis, J., Easton, D., Michailidou, K., Simard, J., Bishop, T., Cheng, I. C., Huyghe, J. R., Schmit, S. L., O'Mara, T. A., Spurdle, A. B., Gharahkhani, P., Schumacher, J., Jankowski, J., Gocke, I., Bondy, M. L., Houlston, R. S., Jenkins, R. B., Melin, B., Lesseur, C., Ness, A. R., Diergaarde, B., Olshan, A. F., Amos, C. I., Christiani, D. C., Landi, M. T., McKay, J. D., Brossard, M., Iles, M. M., Law, M. H., MacGregor, S., Beesley, J., Jones, M. R., Tyrer, J., Winham, S. J., Klein, A. P., Petersen, G., Li, D., Wolpin, B. M., Eeles, R. A., Haiman, C. A., Kote-Jarai, Z., Schumacher, F. R., Brennan, P., Chanock, S. J., Gaborieau, V., Purdue, M. P., Pharoah, P., Hung, R. J., Amundadottir, L. T., Kraft, P., Pasaniuc, B., & Lindström, S. (2021). Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. HGG advances, 2(3), . https://doi.org/10.1016/j.xhgg.2021.100041
Chen, Hongjie, et al. "Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals." HGG advances vol. 2,3 (2021). doi: https://doi.org/10.1016/j.xhgg.2021.100041
Chen H, Majumdar A, Wang L, Kar S, Brown KM, Feng H, Turman C, Dennis J, Easton D, Michailidou K, Simard J, Bishop T, Cheng IC, Huyghe JR, Schmit SL, O'Mara TA, Spurdle AB, Gharahkhani P, Schumacher J, Jankowski J, Gocke I, Bondy ML, Houlston RS, Jenkins RB, Melin B, Lesseur C, Ness AR, Diergaarde B, Olshan AF, Amos CI, Christiani DC, Landi MT, McKay JD, Brossard M, Iles MM, Law MH, MacGregor S, Beesley J, Jones MR, Tyrer J, Winham SJ, Klein AP, Petersen G, Li D, Wolpin BM, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Brennan P, Chanock SJ, Gaborieau V, Purdue MP, Pharoah P, Hung RJ, Amundadottir LT, Kraft P, Pasaniuc B, Lindström S. Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100041. Epub 2021 Jun 12. PMID: 34355204; PMCID: PMC8336922.
Copy Download .nbib Format: NLM
Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.

Cancer research

Patel A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A.
PMID: 34711612
Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28.

Continuous risk of recurrence scores (CRS) based on tumor gene expression are vital prognostic tools for breast cancer. Studies have shown that Black women (BW) have higher CRS than White women (WW). Although systemic injustices contribute substantially to breast...

Cite
Patel A, García-Closas M, Olshan AF, et al. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2021;82(1):25-35doi: 10.1158/0008-5472.CAN-21-1207.
Patel, A., García-Closas, M., Olshan, A. F., Perou, C. M., Troester, M. A., Love, M. I., & Bhattacharya, A. (2022). Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer research, 82(1), 25-35. https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel, Achal, et al. "Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer." Cancer research vol. 82,1 (2022): 25-35. doi: https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28. PMID: 34711612; PMCID: PMC8732329.
Copy Download .nbib Format: NLM
Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer.

NPJ precision oncology

Li S, Xu Y, Zhang Y, Nie L, Ma Z, Ma L, Fang X, Ma X.
PMID: 32923685
NPJ Precis Oncol. 2020 Sep 01;4:25. doi: 10.1038/s41698-020-00131-6. eCollection 2020.

To determine whether genetically predicted circulating levels of cytokines are associated with risk of overall breast cancer (BC), estrogen receptor (ER)-positive and ER-negative BC, we conducted two-sample MR analyses using data from the most comprehensive genome-wide association studies (GWAS)...

Cite
Li S, Xu Y, Zhang Y, et al. Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer. NPJ Precis Oncol. 2020;4:25doi: 10.1038/s41698-020-00131-6.
Li, S., Xu, Y., Zhang, Y., Nie, L., Ma, Z., Ma, L., Fang, X., & Ma, X. (2020). Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer. NPJ precision oncology, 425. https://doi.org/10.1038/s41698-020-00131-6
Li, Shen, et al. "Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer." NPJ precision oncology vol. 4 (2020): 25. doi: https://doi.org/10.1038/s41698-020-00131-6
Li S, Xu Y, Zhang Y, Nie L, Ma Z, Ma L, Fang X, Ma X. Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer. NPJ Precis Oncol. 2020 Sep 01;4:25. doi: 10.1038/s41698-020-00131-6. eCollection 2020. PMID: 32923685; PMCID: PMC7462857.
Copy Download .nbib Format: NLM
[No title available]

Oncotarget

Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, Maguire P, Kremeyer B, Luo L, von Holst S, Kontham V, Thutkawkorapin J, Margolin S, Du Q, Lundin J, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Beckmann MW, Blomqvist C, Blot W, Boeckx B, Bojesen SE, Bonanni B, Brand JS, Brauch H, Brenner H, Broeks A, Brüning T, Burwinkel B, Cai Q, Chang-Claude J, Couch FJ, Cox A, Cross SS, Deming-Halverson SL, Devilee P, Dos-Santos-Silva I, Dörk T, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, García-Closas M, Giles GG, González-Neira A, Guénel P, Guo Q, Gündert M, Haiman CA, Hallberg E, Hamann U, Harrington P, Hooning MJ, Hopper JL, Huang G, Jakubowska A, Jones ME, Kerin MJ, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Lubinski J, Mannermaa A, Martens JWM, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Peto J, Pylkäs K, Radice P, Rhenius V, Sawyer EJ, Schmidt MK, Schmutzler RK, Seynaeve C, Shah M, Simard J, Southey MC, Swerdlow AJ, Truong T, Wendt C, Winqvist R, Zheng W, Benitez J, Dunning AM, Pharoah PDP, Easton DF, Czene K, Hall P, Lindblom A.
PMID: 29262523
Oncotarget. 2017 Oct 12;8(61):102769-102782. doi: 10.18632/oncotarget.21800. eCollection 2017 Nov 28.

Most non-

Cite
Jiao X, Aravidis C, Marikkannu R, et al. . Oncotarget. 2017;8(61):102769-102782doi: 10.18632/oncotarget.21800.
Jiao, X., Aravidis, C., Marikkannu, R., Rantala, J., Picelli, S., Adamovic, T., Liu, T., Maguire, P., Kremeyer, B., Luo, L., von Holst, S., Kontham, V., Thutkawkorapin, J., Margolin, S., Du, Q., Lundin, J., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Lush, M., Ambrosone, C. B., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Beckmann, M. W., Blomqvist, C., Blot, W., Boeckx, B., Bojesen, S. E., Bonanni, B., Brand, J. S., Brauch, H., Brenner, H., Broeks, A., Brüning, T., Burwinkel, B., Cai, Q., Chang-Claude, J., Couch, F. J., Cox, A., Cross, S. S., Deming-Halverson, S. L., Devilee, P., Dos-Santos-Silva, I., Dörk, T., Eriksson, M., Fasching, P. A., Figueroa, J., Flesch-Janys, D., Flyger, H., Gabrielson, M., García-Closas, M., Giles, G. G., González-Neira, A., Guénel, P., Guo, Q., Gündert, M., Haiman, C. A., Hallberg, E., Hamann, U., Harrington, P., Hooning, M. J., Hopper, J. L., Huang, G., Jakubowska, A., Jones, M. E., Kerin, M. J., Kosma, V. M., Kristensen, V. N., Lambrechts, D., Le Marchand, L., Lubinski, J., Mannermaa, A., Martens, J. W. M., Meindl, A., Milne, R. L., Mulligan, A. M., Neuhausen, S. L., Nevanlinna, H., Peto, J., Pylkäs, K., Radice, P., Rhenius, V., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Seynaeve, C., Shah, M., Simard, J., Southey, M. C., Swerdlow, A. J., Truong, T., Wendt, C., Winqvist, R., Zheng, W., Benitez, J., Dunning, A. M., Pharoah, P. D. P., Easton, D. F., Czene, K., Hall, P., & Lindblom, A. (2017). . Oncotarget, 8(61), 102769-102782. https://doi.org/10.18632/oncotarget.21800
Jiao, Xiang, et al. "." Oncotarget vol. 8,61 (2017): 102769-102782. doi: https://doi.org/10.18632/oncotarget.21800
Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, Maguire P, Kremeyer B, Luo L, von Holst S, Kontham V, Thutkawkorapin J, Margolin S, Du Q, Lundin J, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Beckmann MW, Blomqvist C, Blot W, Boeckx B, Bojesen SE, Bonanni B, Brand JS, Brauch H, Brenner H, Broeks A, Brüning T, Burwinkel B, Cai Q, Chang-Claude J, Couch FJ, Cox A, Cross SS, Deming-Halverson SL, Devilee P, Dos-Santos-Silva I, Dörk T, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, García-Closas M, Giles GG, González-Neira A, Guénel P, Guo Q, Gündert M, Haiman CA, Hallberg E, Hamann U, Harrington P, Hooning MJ, Hopper JL, Huang G, Jakubowska A, Jones ME, Kerin MJ, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Lubinski J, Mannermaa A, Martens JWM, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Peto J, Pylkäs K, Radice P, Rhenius V, Sawyer EJ, Schmidt MK, Schmutzler RK, Seynaeve C, Shah M, Simard J, Southey MC, Swerdlow AJ, Truong T, Wendt C, Winqvist R, Zheng W, Benitez J, Dunning AM, Pharoah PDP, Easton DF, Czene K, Hall P, Lindblom A. . Oncotarget. 2017 Oct 12;8(61):102769-102782. doi: 10.18632/oncotarget.21800. eCollection 2017 Nov 28. PMID: 29262523; PMCID: PMC5732689.
Copy Download .nbib Format: NLM
Association of germline variation with the survival of women with .

NPJ breast cancer

Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB, Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ, Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN, Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H.
PMID: 32964118
NPJ Breast Cancer. 2020 Sep 10;6:44. doi: 10.1038/s41523-020-00185-6. eCollection 2020.

Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline...

Cite
Muranen TA, Khan S, Fagerholm R, et al. Association of germline variation with the survival of women with . NPJ Breast Cancer. 2020;6:44doi: 10.1038/s41523-020-00185-6.
Muranen, T. A., Khan, S., Fagerholm, R., Aittomäki, K., Cunningham, J. M., Dennis, J., Leslie, G., McGuffog, L., Parsons, M. T., Simard, J., Slager, S., Soucy, P., Easton, D. F., Tischkowitz, M., Spurdle, A. B., Schmutzler, R. K., Wappenschmidt, B., Hahnen, E., Hooning, M. J., Singer, C. F., Wagner, G., Thomassen, M., Pedersen, I. S., Domchek, S. M., Nathanson, K. L., Lazaro, C., Rossing, C. M., Andrulis, I. L., Teixeira, M. R., James, P., Garber, J., Weitzel, J. N., Jakubowska, A., Yannoukakos, D., John, E. M., Southey, M. C., Schmidt, M. K., Antoniou, A. C., Chenevix-Trench, G., Blomqvist, C., & Nevanlinna, H. (2020). Association of germline variation with the survival of women with . NPJ breast cancer, 644. https://doi.org/10.1038/s41523-020-00185-6
Muranen, Taru A, et al. "Association of germline variation with the survival of women with ." NPJ breast cancer vol. 6 (2020): 44. doi: https://doi.org/10.1038/s41523-020-00185-6
Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB, Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ, Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN, Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H. Association of germline variation with the survival of women with . NPJ Breast Cancer. 2020 Sep 10;6:44. doi: 10.1038/s41523-020-00185-6. eCollection 2020. PMID: 32964118; PMCID: PMC7483417.
Copy Download .nbib Format: NLM
Genetic Evidence for the Association between Schizophrenia and Breast Cancer.

Journal of psychiatry and brain science

Shi J, Wu L, Zheng W, Wen W, Wang S, Shu X, Long J, Shen CY, Wu PE, Saloustros E, Chang-Claude J, Brenner H, Shu XO, Cai Q.
PMID: 30854469
J Psychiatr Brain Sci. 2018;3(4). doi: 10.20900/jpbs.20180007. Epub 2018 Aug 08.

OBJECTIVE: To estimate the potential effect of schizophrenia on breast cancer risk in women, we performed a two-sample Mendelian randomization (MR) study.METHODS: The instrumental variables comprised 170 uncorrelated and non-pleiotropic single nucleotide polymorphisms (SNPs) that are significantly associated with...

Cite
Shi J, Wu L, Zheng W, et al. Genetic Evidence for the Association between Schizophrenia and Breast Cancer. J Psychiatr Brain Sci. 2018;3(4)doi: 10.20900/jpbs.20180007.
Shi, J., Wu, L., Zheng, W., Wen, W., Wang, S., Shu, X., Long, J., Shen, C. Y., Wu, P. E., Saloustros, E., Chang-Claude, J., Brenner, H., Shu, X. O., & Cai, Q. (2018). Genetic Evidence for the Association between Schizophrenia and Breast Cancer. Journal of psychiatry and brain science, 3(4), . https://doi.org/10.20900/jpbs.20180007
Shi, Jiajun, et al. "Genetic Evidence for the Association between Schizophrenia and Breast Cancer." Journal of psychiatry and brain science vol. 3,4 (2018). doi: https://doi.org/10.20900/jpbs.20180007
Shi J, Wu L, Zheng W, Wen W, Wang S, Shu X, Long J, Shen CY, Wu PE, Saloustros E, Chang-Claude J, Brenner H, Shu XO, Cai Q. Genetic Evidence for the Association between Schizophrenia and Breast Cancer. J Psychiatr Brain Sci. 2018;3(4). doi: 10.20900/jpbs.20180007. Epub 2018 Aug 08. PMID: 30854469; PMCID: PMC6402491.
Copy Download .nbib Format: NLM
Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease.

Prostate cancer and prostatic diseases

Sipeky C, Tammela TLJ, Auvinen A, Schleutker J.
PMID: 34012061
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1158-1166. doi: 10.1038/s41391-021-00378-5. Epub 2021 May 19.

Prostate cancer (PrCa) is one of the most common cancers in men, but little is known about factors affecting its clinical outcomes. Genome-wide association studies have identified more than 170 germline susceptibility loci, but most of them are not...

Cite
Sipeky C, Tammela TLJ, Auvinen A, et al. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer Prostatic Dis. 2021;24(4):1158-1166doi: 10.1038/s41391-021-00378-5.
Sipeky, C., Tammela, T. L. J., Auvinen, A., & Schleutker, J. (2021). Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate cancer and prostatic diseases, 24(4), 1158-1166. https://doi.org/10.1038/s41391-021-00378-5
Sipeky, Csilla, et al. "Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease." Prostate cancer and prostatic diseases vol. 24,4 (2021): 1158-1166. doi: https://doi.org/10.1038/s41391-021-00378-5
Sipeky C, Tammela TLJ, Auvinen A, Schleutker J. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1158-1166. doi: 10.1038/s41391-021-00378-5. Epub 2021 May 19. PMID: 34012061; PMCID: PMC8616752.
Copy Download .nbib Format: NLM
Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals.

HGG advances

Chen H, Majumdar A, Wang L, Kar S, Brown KM, Feng H, Turman C, Dennis J, Easton D, Michailidou K, Simard J, Bishop T, Cheng IC, Huyghe JR, Schmit SL, O'Mara TA, Spurdle AB, Gharahkhani P, Schumacher J, Jankowski J, Gocke I, Bondy ML, Houlston RS, Jenkins RB, Melin B, Lesseur C, Ness AR, Diergaarde B, Olshan AF, Amos CI, Christiani DC, Landi MT, McKay JD, Brossard M, Iles MM, Law MH, MacGregor S, Beesley J, Jones MR, Tyrer J, Winham SJ, Klein AP, Petersen G, Li D, Wolpin BM, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Brennan P, Chanock SJ, Gaborieau V, Purdue MP, Pharoah P, Hung RJ, Amundadottir LT, Kraft P, Pasaniuc B, Lindström S.
PMID: 34355204
HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100041. Epub 2021 Jun 12.

Genome-wide association studies (GWASs) have identified thousands of cancer risk loci revealing many risk regions shared across multiple cancers. Characterizing the cross-cancer shared genetic basis can increase our understanding of global mechanisms of cancer development. In this study, we...

Cite
Chen H, Majumdar A, Wang L, et al. Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. HGG Adv. 2021;2(3)doi: 10.1016/j.xhgg.2021.100041.
Chen, H., Majumdar, A., Wang, L., Kar, S., Brown, K. M., Feng, H., Turman, C., Dennis, J., Easton, D., Michailidou, K., Simard, J., Bishop, T., Cheng, I. C., Huyghe, J. R., Schmit, S. L., O'Mara, T. A., Spurdle, A. B., Gharahkhani, P., Schumacher, J., Jankowski, J., Gocke, I., Bondy, M. L., Houlston, R. S., Jenkins, R. B., Melin, B., Lesseur, C., Ness, A. R., Diergaarde, B., Olshan, A. F., Amos, C. I., Christiani, D. C., Landi, M. T., McKay, J. D., Brossard, M., Iles, M. M., Law, M. H., MacGregor, S., Beesley, J., Jones, M. R., Tyrer, J., Winham, S. J., Klein, A. P., Petersen, G., Li, D., Wolpin, B. M., Eeles, R. A., Haiman, C. A., Kote-Jarai, Z., Schumacher, F. R., Brennan, P., Chanock, S. J., Gaborieau, V., Purdue, M. P., Pharoah, P., Hung, R. J., Amundadottir, L. T., Kraft, P., Pasaniuc, B., & Lindström, S. (2021). Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. HGG advances, 2(3), . https://doi.org/10.1016/j.xhgg.2021.100041
Chen, Hongjie, et al. "Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals." HGG advances vol. 2,3 (2021). doi: https://doi.org/10.1016/j.xhgg.2021.100041
Chen H, Majumdar A, Wang L, Kar S, Brown KM, Feng H, Turman C, Dennis J, Easton D, Michailidou K, Simard J, Bishop T, Cheng IC, Huyghe JR, Schmit SL, O'Mara TA, Spurdle AB, Gharahkhani P, Schumacher J, Jankowski J, Gocke I, Bondy ML, Houlston RS, Jenkins RB, Melin B, Lesseur C, Ness AR, Diergaarde B, Olshan AF, Amos CI, Christiani DC, Landi MT, McKay JD, Brossard M, Iles MM, Law MH, MacGregor S, Beesley J, Jones MR, Tyrer J, Winham SJ, Klein AP, Petersen G, Li D, Wolpin BM, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Brennan P, Chanock SJ, Gaborieau V, Purdue MP, Pharoah P, Hung RJ, Amundadottir LT, Kraft P, Pasaniuc B, Lindström S. Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. HGG Adv. 2021 Jul 08;2(3). doi: 10.1016/j.xhgg.2021.100041. Epub 2021 Jun 12. PMID: 34355204; PMCID: PMC8336922.
Copy Download .nbib Format: NLM
Identification of a Locus Near .

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Quinn MCJ, McCue K, Shi W, Johnatty SE, Beesley J, Civitarese A, O'Mara TA, Glubb DM, Tyrer JP, Armasu SM, Ong JS, Gharahkhani P, Lu Y, Gao B, Patch AM, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Velez Edwards DR, Beeghly-Fadiel A, Benitez J, Garcia MJ, Goodman MT, Dörk T, Dürst M, Modugno F, Moysich K, du Bois A, Pfisterer J, Bauman K, Karlan BY, Lester J, Cunningham JM, Larson MC, McCauley BM, Kjaer SK, Jensen A, Hogdall CK, Hogdall E, Schildkraut JM, Riggan MJ, Berchuck A, Cramer DW, Terry KL, Bjorge L, Webb PM, Friedlander M, Pejovic T, Moffitt M, Glasspool R, May T, Ene GEV, Huntsman DG, Woo M, Carney ME, Hinsley S, Heitz F, Fereday S, Kennedy CJ, Edwards SL, Winham SJ, deFazio A, Pharoah PDP, Goode EL, MacGregor S, Chenevix-Trench G.
PMID: 34162658
Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1669-1680. doi: 10.1158/1055-9965.EPI-20-1817. Epub 2021 Jun 23.

BACKGROUND: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels...

Cite
Quinn MCJ, McCue K, Shi W, et al. Identification of a Locus Near . Cancer Epidemiol Biomarkers Prev. 2021;30(9):1669-1680doi: 10.1158/1055-9965.EPI-20-1817.
Quinn, M. C. J., McCue, K., Shi, W., Johnatty, S. E., Beesley, J., Civitarese, A., O'Mara, T. A., Glubb, D. M., Tyrer, J. P., Armasu, S. M., Ong, J. S., Gharahkhani, P., Lu, Y., Gao, B., Patch, A. M., Fasching, P. A., Beckmann, M. W., Lambrechts, D., Vergote, I., Velez Edwards, D. R., Beeghly-Fadiel, A., Benitez, J., Garcia, M. J., Goodman, M. T., Dörk, T., Dürst, M., Modugno, F., Moysich, K., du Bois, A., Pfisterer, J., Bauman, K., Karlan, B. Y., Lester, J., Cunningham, J. M., Larson, M. C., McCauley, B. M., Kjaer, S. K., Jensen, A., Hogdall, C. K., Hogdall, E., Schildkraut, J. M., Riggan, M. J., Berchuck, A., Cramer, D. W., Terry, K. L., Bjorge, L., Webb, P. M., Friedlander, M., Pejovic, T., Moffitt, M., Glasspool, R., May, T., Ene, G. E. V., Huntsman, D. G., Woo, M., Carney, M. E., Hinsley, S., Heitz, F., Fereday, S., Kennedy, C. J., Edwards, S. L., Winham, S. J., deFazio, A., Pharoah, P. D. P., Goode, E. L., MacGregor, S., Chenevix-Trench, G. (2021). Identification of a Locus Near . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(9), 1669-1680. https://doi.org/10.1158/1055-9965.EPI-20-1817
Quinn, Michael C J, et al. "Identification of a Locus Near ." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,9 (2021): 1669-1680. doi: https://doi.org/10.1158/1055-9965.EPI-20-1817
Quinn MCJ, McCue K, Shi W, Johnatty SE, Beesley J, Civitarese A, O'Mara TA, Glubb DM, Tyrer JP, Armasu SM, Ong JS, Gharahkhani P, Lu Y, Gao B, Patch AM, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Velez Edwards DR, Beeghly-Fadiel A, Benitez J, Garcia MJ, Goodman MT, Dörk T, Dürst M, Modugno F, Moysich K, du Bois A, Pfisterer J, Bauman K, Karlan BY, Lester J, Cunningham JM, Larson MC, McCauley BM, Kjaer SK, Jensen A, Hogdall CK, Hogdall E, Schildkraut JM, Riggan MJ, Berchuck A, Cramer DW, Terry KL, Bjorge L, Webb PM, Friedlander M, Pejovic T, Moffitt M, Glasspool R, May T, Ene GEV, Huntsman DG, Woo M, Carney ME, Hinsley S, Heitz F, Fereday S, Kennedy CJ, Edwards SL, Winham SJ, deFazio A, Pharoah PDP, Goode EL, MacGregor S, Chenevix-Trench G. Identification of a Locus Near . Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1669-1680. doi: 10.1158/1055-9965.EPI-20-1817. Epub 2021 Jun 23. PMID: 34162658; PMCID: PMC8419101.
Copy Download .nbib Format: NLM
A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk.

International journal of cancer

Liu D, Zhu J, Zhou D, Nikas EG, Mitanis NT, Sun Y, Wu C, Mancuso N, Cox NJ, Wang L, Freedland SJ, Haiman CA, Gamazon ER, Nikas JB, Wu L.
PMID: 34520569
Int J Cancer. 2022 Jan 01;150(1):80-90. doi: 10.1002/ijc.33808. Epub 2021 Sep 25.

A large proportion of heritability for prostate cancer risk remains unknown. Transcriptome-wide association study combined with validation comparing overall levels will help to identify candidate genes potentially playing a role in prostate cancer development. Using data from the Genotype-Tissue...

Cite
Liu D, Zhu J, Zhou D, et al. A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. Int J Cancer. 2021;150(1):80-90doi: 10.1002/ijc.33808.
Liu, D., Zhu, J., Zhou, D., Nikas, E. G., Mitanis, N. T., Sun, Y., Wu, C., Mancuso, N., Cox, N. J., Wang, L., Freedland, S. J., Haiman, C. A., Gamazon, E. R., Nikas, J. B., & Wu, L. (2022). A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. International journal of cancer, 150(1), 80-90. https://doi.org/10.1002/ijc.33808
Liu, Duo, et al. "A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk." International journal of cancer vol. 150,1 (2022): 80-90. doi: https://doi.org/10.1002/ijc.33808
Liu D, Zhu J, Zhou D, Nikas EG, Mitanis NT, Sun Y, Wu C, Mancuso N, Cox NJ, Wang L, Freedland SJ, Haiman CA, Gamazon ER, Nikas JB, Wu L. A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. Int J Cancer. 2022 Jan 01;150(1):80-90. doi: 10.1002/ijc.33808. Epub 2021 Sep 25. PMID: 34520569; PMCID: PMC8595764.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries